NO952744L - Cytokinbegrensende midler - Google Patents

Cytokinbegrensende midler

Info

Publication number
NO952744L
NO952744L NO952744A NO952744A NO952744L NO 952744 L NO952744 L NO 952744L NO 952744 A NO952744 A NO 952744A NO 952744 A NO952744 A NO 952744A NO 952744 L NO952744 L NO 952744L
Authority
NO
Norway
Prior art keywords
cytokine
subject
limiting agents
provides
methods
Prior art date
Application number
NO952744A
Other languages
English (en)
Other versions
NO952744D0 (no
Inventor
Mark J Suto
Beverly E Girten
Richard A Houghten
Costas C Loullis
Ronald R Tuttle
Original Assignee
Houghten Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Houghten Pharm Inc filed Critical Houghten Pharm Inc
Publication of NO952744D0 publication Critical patent/NO952744D0/no
Publication of NO952744L publication Critical patent/NO952744L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Abstract

Nye Cytokinbegrensende midler som begrenser eller kontrollerer den biologiske aktivitet av cytokiner. Farmasøytiske preparater omfattende et Cytokinbegrensende peptid og fremgangs- måter for administrering av det farma- søytiske preparat til et subjekt er også beskrevet. Fremgangsmåter for an- vendelse av de nye peptider til å begrense cytokinaktivitet i et subjekt er også beskrevet. Det Cytokinbegrensende peptidet har den generelle fornelen: hvori Y «r O, H, eller S: R, er H, COCH,. C,H,, CH.Ph. COPh, COO-t-butyl. COOCH,Ph, CH,CO-(polyotylenglykol) eller A; R, er H eller COCH,; R, er on llno«r eller forgrenet alkylgruppe med l til 6 korbonatomer eller en syklisk alkylgruppe «ed 3 til 6 karbonatoner; R. er (CH,).-CONH,, (CH,).-CONHR, eller <CH,).-CONKA: R, er OH, OR,, NH,, SH, NHCH,. HHCH,Ph eller A: og R, er H eller R,; og hvori 'Ph' er C,H,, 'm* er 1. 2 eller 3. "n" er O, l, 2 eller 3. og "A* er et karbohydrat med den generelle formel: K(0 X, - x, - Hi. - (D)Phe - Arg - (D)Trp - X,.
NO952744A 1993-11-12 1995-07-11 Cytokinbegrensende midler NO952744L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/151,534 US5420109A (en) 1993-11-12 1993-11-12 Cytokine restraining agents
PCT/US1994/012897 WO1995013086A1 (en) 1993-11-12 1994-11-09 Cytokine restraining agents

Publications (2)

Publication Number Publication Date
NO952744D0 NO952744D0 (no) 1995-07-11
NO952744L true NO952744L (no) 1995-09-08

Family

ID=22539190

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952744A NO952744L (no) 1993-11-12 1995-07-11 Cytokinbegrensende midler

Country Status (14)

Country Link
US (3) US5420109A (no)
EP (1) EP0679092B1 (no)
JP (2) JP2793719B2 (no)
KR (1) KR100248033B1 (no)
AT (1) ATE179429T1 (no)
CA (1) CA2153584C (no)
DE (1) DE69418181T2 (no)
DK (1) DK0679092T3 (no)
ES (1) ES2130574T3 (no)
FI (1) FI953378A0 (no)
GR (1) GR3030382T3 (no)
NO (1) NO952744L (no)
NZ (1) NZ276906A (no)
WO (1) WO1995013086A1 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741774A (en) * 1993-11-12 1998-04-21 Trega Biosciences, Inc. Use of a cytokine regulatory agent to treat rheumatoid arthritis
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5888978A (en) * 1995-09-12 1999-03-30 Trega Biosciences, Inc. Method for reducing the severity of gastro-intestinal damage
US6841533B1 (en) 1995-12-07 2005-01-11 Peptor Limited Conformationally constrained backbone cyclized interleukin-6 antagonists
IL130238A0 (en) * 1999-06-01 2000-06-01 Peptor Ltd Conformationally constrained backbone cyclized interleukin-6 antagonists
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
WO1998013032A1 (en) * 1996-09-27 1998-04-02 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
US20020197250A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US20020198487A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in physiologic fluids
US20020197249A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products
US8329388B2 (en) * 1997-07-30 2012-12-11 Cytosorbents, Inc. Biocompatible devices, systems, and methods for reducing levels of proinflammatory of antiinflammatory stimulators or mediators in the blood
US20020159995A1 (en) * 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
CA2324115C (en) 1998-03-17 2008-12-23 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
WO1999055679A1 (en) 1998-04-28 1999-11-04 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
EP1593384A3 (en) * 1999-06-29 2006-04-26 Palatin Technologies, Inc. Compositions for treatment of sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
WO2001005401A1 (en) * 1999-07-16 2001-01-25 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
US6921530B1 (en) 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6878127B2 (en) 2001-04-10 2005-04-12 Renaltech International, Llc Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
WO2002085933A1 (en) * 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US8703146B2 (en) * 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
JP2004534851A (ja) * 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． メラノコルチン受容体に特異的な線状および環状ペプチド
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7067621B2 (en) * 2002-08-20 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Multifunctional context-activated protides and methods of use
DE60329402D1 (de) * 2002-08-23 2009-11-05 Inst Medical W & E Hall Behandlungs- und prophylaxeverfahren
AU2002950957A0 (en) * 2002-08-23 2002-09-12 The Walter And Eliza Hall Institute Of Medical Research A method of treatment and prophylaxis
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
FR2869531B1 (fr) * 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
KR20080018980A (ko) * 2004-04-30 2008-02-29 아이게이트 파르마 에스아에스 자극 감소형의 안구용 이온 영동 장치
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
TWI334784B (en) * 2006-04-14 2010-12-21 Buck Inst For Age Res Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2370155B1 (en) 2008-12-31 2018-07-04 Eyegate Pharmaceuticals, Inc. System for ocular iontophoresis with buffering
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
JP6294074B2 (ja) 2010-04-27 2018-03-14 エータイアー ファーマ， インコーポレイテッド イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CA2797978C (en) 2010-05-03 2019-12-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
CN103096912A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN102985103A (zh) 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
JP6396656B2 (ja) 2010-05-14 2018-09-26 エータイアー ファーマ， インコーポレイテッド フェニルアラニルβｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6027965B2 (ja) 2010-05-17 2016-11-16 エータイアー ファーマ， インコーポレイテッド ロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US8962560B2 (en) 2010-06-01 2015-02-24 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
CA2804416C (en) 2010-07-12 2020-04-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
RU2659423C2 (ru) 2012-02-16 2018-07-02 ЭйТИР ФАРМА, ИНК. ГИСТИДИЛ-тРНК-СИНТЕТАЗЫ ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
DK3460054T3 (da) 2013-03-15 2021-01-18 Atyr Pharma Inc Histidyl-tRNA-syntetase-Fc-konjugater
US9839625B2 (en) 2014-11-06 2017-12-12 Northwestern University Inhibition of cancer cell motility
JP2020517638A (ja) 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) * 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US4649191A (en) * 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
US5157023A (en) * 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
US5028592A (en) * 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
ATE84420T1 (de) * 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
DE3851002T2 (de) * 1987-05-22 1995-02-02 University Patents Inc Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
EP0293837B1 (en) * 1987-06-01 1992-01-15 Keikichi Sugiyama Composition for application to hair or scalp
US5049547A (en) * 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US5114960A (en) * 1989-07-20 1992-05-19 Hoffmann-La Roche Inc. Substituted isoxazole derivatives
ZA908610B (en) * 1989-11-03 1991-08-28 Univ Tulane Peptides aiding nerve regeneration
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5741774A (en) * 1993-11-12 1998-04-21 Trega Biosciences, Inc. Use of a cytokine regulatory agent to treat rheumatoid arthritis
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents

Also Published As

Publication number Publication date
DE69418181D1 (de) 1999-06-02
US5420109A (en) 1995-05-30
US5888969A (en) 1999-03-30
ES2130574T3 (es) 1999-07-01
ATE179429T1 (de) 1999-05-15
CA2153584A1 (en) 1995-05-18
JP2793719B2 (ja) 1998-09-03
DK0679092T3 (da) 1999-11-08
NO952744D0 (no) 1995-07-11
JPH10259196A (ja) 1998-09-29
AU678329B2 (en) 1997-05-22
AU1174195A (en) 1995-05-29
EP0679092A4 (en) 1997-11-19
FI953378A (fi) 1995-07-10
EP0679092B1 (en) 1999-04-28
KR100248033B1 (ko) 2000-04-01
DE69418181T2 (de) 1999-12-23
NZ276906A (en) 1997-05-26
CA2153584C (en) 2000-05-09
EP0679092A1 (en) 1995-11-02
JP3357883B2 (ja) 2002-12-16
FI953378A0 (fi) 1995-07-10
US6245738B1 (en) 2001-06-12
WO1995013086A1 (en) 1995-05-18
GR3030382T3 (en) 1999-09-30
JPH08508299A (ja) 1996-09-03

Similar Documents

Publication Publication Date Title
NO952744D0 (no) Cytokinbegrensende midler
CA2189250A1 (en) Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
IL102848A0 (en) Polypeptides having growth hormone releasing activity,their use and pharmaceutical compositions containing them
HK1097449A1 (en) Methods for in vivo delivery of biologics and compositions useful therefor
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
TR199802423T2 (xx) Konsantre antikor terkibi.
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
DE1019040T1 (de) Hemmung von p38 kinase aktivität durch arylharnstoff
NO954722L (no) Peptid inhibitorer med urokinase reseptoraktivitet
ATE187740T1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
FR2694296B1 (fr) Peptides inhibant l&#39;activité des protéines ras, préparation et utilisation.
BR0312889A (pt) Polipeptìdeo t20 peguilado
MX9204240A (es) Montaje distribuidor y de mezclado de dos etapas para preparaciones tal como cementos dentales.
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
DK0719276T3 (da) Ïstradiolestre med stærk oral virkning samt farmaceutiske præparater med indhold deraf
IL106591A0 (en) An interferon alpha/beta binding protein,its preparation and pharmaceutical compositions containing it
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE69626050D1 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
ATE283279T1 (de) Therapeutische inhaltsstoffe
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
EP0190860A3 (en) 6-chloro-3-methyl-1h-2,3,4,5-tetrahydro-3-benzazepine-n-oxide and medical compositions using it

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application